Krishna Institute of Medical Sciences Ltd

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA by 2 agencies.
• ResultsProfit fallingIn the Jun 2026 quarter, sales rose 35% and profit fell 57% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 32%, down from 34% in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 141.9 times its yearly earnings (P/E), pricier than 95% of the time in the last 5 years. Its usual P/E is about 51.

Krishna Institute of Medical Sciences Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)141.9 against a typical 48.9: pricier than most peers (1st = cheapest).37th of 40
• Sales growth+35.3% against a typical +21.1% from a year earlier.9th of 34
• Profit growth−56.5% against a typical +13% from a year earlier.26th of 31
• Share price, 3 months−11.7% against a typical −10.9%.18th of 34
• Size₹ 27,847.9 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).8th of 36

Exchange filings and their impact on the company.

• 7 Oct 2026General UpdatesLow impactPositivePrice +0.1% that day
  KIMS cut target financials ~90% to Rs 9.7 cr turnover and Rs 7.1 cr PAT, confirming a tiny bolt-on deal.

  KIMS issued a correction to its 6th October filing on two target companies. Insignia Healthcare net worth was cut from Rs 243.3 crore to Rs 24.3 crore and turnover from Rs 104.5 crore to Rs 9.68 crore, while Sarvottam Health Care PAT was cut from Rs 70.55 crore to Rs 7.06 crore. All other terms remain unchanged. The corrected figures show the targets are very small compared to KIMS FY26 revenue of Rs 3,905 crore, implying only a marginal tuck-in impact over the next year.

  Full analysisFiling
• 6 Oct 2026AcquisitionLow impactPositivePrice +0.1% on 7 Oct
  KIMS to invest Rs 15 cr for 6% of 316-bed Sangli hospital plus exclusive O&M rights under KIMS-UAIMS brand.

  On 6 Oct 2026, KIMS board approved acquiring a 6% stake in Ushahkal Abhinav Specialty Hospital LLP in Sangli for up to Rs 15 crore via primary infusion, to close by 31 Oct 2026. The target is a 316-bed quaternary care hospital expandable to over 500 beds, with FY26 turnover of Rs 80.42 crore, loss of Rs 23.59 crore and net worth of Rs 116.42 crore. KIMS will also exclusively manage and operate the hospital as KIMS-UAIMS, adding a strategic Maharashtra footprint with minimal capital outlay.

  Full analysisFiling
• 6 Oct 2026AcquisitionLow impactPositivePrice +0.1% on 7 Oct
  KIMS to buy up to 51% of 150-bed Guntur hospital over 12-24 months - small growth add with near-term loss drag.

  KIMS board on 6 Oct 2026 approved buying up to 51% of Insignia Healthcare (KIMS-SIKHARA) in Guntur for cash at Rs 30.35 per share, via creeping acquisition over 12-24 months. The target runs a 150-bed hospital expandable to 200 beds, which KIMS already operates and manages, with FY25 turnover of Rs 9.68 cr (history table shows Rs 104.5 cr) and PAT of Rs -13.28 cr. It secures a small strategic bed addition in its home market, adding modest revenue but a small initial loss and funding outflow.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Bhaskara Rao Bollineni

Executive Chairman of the Board, Managing Director

Abhinay Bollineni

Chief Executive Officer, Executive Director

Sachin Ashok Salvi

Chief Financial Officer

Nagajayanthi Juttur Raghavendra Das

Company Secretary and Compliance Officer

Adwik Bollineni

Executive Director

Anitha Dandamudi

Whole-time Director